<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" xml:lang="EN">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">MIN</journal-id>
<journal-id journal-id-type="hwp">spmin</journal-id>
<journal-title>Menopause International</journal-title>
<issn pub-type="ppub">1754-0453</issn>
<issn pub-type="epub">1754-0461</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/1754045313487720</article-id>
<article-id pub-id-type="publisher-id">10.1177_1754045313487720</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Review articles</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Androgens and cardiovascular disease: Gender-related differences</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Spoletini</surname><given-names>Ilaria</given-names></name>
<xref ref-type="aff" rid="aff1-1754045313487720">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Caprio</surname><given-names>Massimiliano</given-names></name>
<xref ref-type="aff" rid="aff1-1754045313487720">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Vitale</surname><given-names>Cristiana</given-names></name>
<xref ref-type="aff" rid="aff1-1754045313487720">1</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Rosano</surname><given-names>Giuseppe MC</given-names></name>
<xref ref-type="aff" rid="aff1-1754045313487720">1</xref>
<xref ref-type="aff" rid="aff2-1754045313487720">2</xref>
<xref ref-type="corresp" rid="corresp1-1754045313487720"/>
</contrib>
</contrib-group>
<aff id="aff1-1754045313487720"><label>1</label>Centre for Clinical and Basic Research, Department of Medical Sciences, IRCCS San Raffaele Pisana, Rome, Italy</aff>
<aff id="aff2-1754045313487720"><label>2</label>Laboratory of Vascular Physiology, IRCCS San Raffaele, London, United Kingdom</aff>
<author-notes>
<corresp id="corresp1-1754045313487720">Giuseppe Rosano, Centre for Clinical &amp; Basic Research, IRCCS San Raffaele Pisana, via della Pisana, 235, 00163 Rome, Italy. Email: <email>giuseppe.rosano@sanraffaele.it</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>6</month>
<year>2013</year>
</pub-date>
<volume>19</volume>
<issue>2</issue>
<fpage>82</fpage>
<lpage>86</lpage>
<permissions>
<copyright-statement>© The Author(s) 2013 Reprints and permissions: sagepub.co.uk/journalsPermissions.nav</copyright-statement>
<copyright-year>2013</copyright-year>
<copyright-holder content-type="society">British Menopause Society</copyright-holder>
</permissions>
<abstract>
<p>Androgens are known to play a pivotal role in cardiovascular function. However, a definitive explanation as to how their impact differs between genders is yet to be provided. In this review, the existing studies on the link between androgens and cardiovascular disease have been analysed, with a particular focus on the gender-specific differences. Several studies agree that both direct and indirect effects of testosterone on cardiovascular function show a gender-related dimorphism. Consistently, men and women display different responses to androgen supplementation treatment. Post-menopausal women may particularly benefit from testosterone supplementation therapy. Future studies should further clarify the optimal dose and route of administration of testosterone, and more women should be included in clinical trials, in order to identify novel gender-specific targets, and finally to develop therapeutic strategies.</p>
</abstract>
<kwd-group>
<kwd>Androgens</kwd>
<kwd>testosterone</kwd>
<kwd>sex</kwd>
<kwd>post-menopausal women</kwd>
</kwd-group>
<custom-meta-wrap>
<custom-meta>
<meta-name>edited-state</meta-name>
<meta-value>corrected-proof</meta-value>
</custom-meta>
</custom-meta-wrap>
</article-meta>
</front>
<body>
<sec id="sec1-1754045313487720" sec-type="intro"><title>Introduction</title>
<p>In recent years, there has been growing interest and increasing recognition of the influence of gender-related differences in cardiovascular (CV) function and treatment.<sup><xref ref-type="bibr" rid="bibr1-1754045313487720">1</xref>,<xref ref-type="bibr" rid="bibr2-1754045313487720">2</xref></sup> Both estrogens and androgens are implicated in the development of CV disease and hypertension. Indeed, female and male sex hormones directly affect cardiac function, endothelial function and vascular tone through both genomic and non-genomic effects that are mainly receptor-dependent.<sup><xref ref-type="bibr" rid="bibr3-1754045313487720">3</xref></sup> However, while estrogens are considered to play a positive role on CV health, it has been long debated whether androgens play a detrimental or, conversely, a protective role on CV function.<sup><xref ref-type="bibr" rid="bibr4-1754045313487720">4</xref></sup> Moreover, a definitive answer as to whether testosterone affects risk for CV disease in a gender-dimorphic way is yet to be provided.</p>
<p>In this review, we will discuss the existing studies regarding the link between androgens and CV disease, with a focus on sex-related differences. The terms “sex”, which is genetically determined, and “gender”, which is related to social factors, will be here used as synonyms.</p>
</sec>
<sec id="sec2-1754045313487720"><title>Androgens and cardiovascular function: risk or benefit?</title>
<p>Androgens in general, and testosterone in particular, have been assumed to play a pivotal role in determining the risk of CV disease.<sup><xref ref-type="bibr" rid="bibr4-1754045313487720">4</xref></sup> The effects of testosterone on CV disease have been investigated since early 1940s, resulting in a proliferation of cross-sectional and prospective studies on this topic for decades. Briefly, speculations on the relationship between testosterone and CV risk can be summarised as follows. On the one hand, it has been argued that high testosterone levels increase the risk for CV disease, although a clear causal link has never been proven.<sup><xref ref-type="bibr" rid="bibr5-1754045313487720">5</xref></sup> Observations supporting this hypothesis are that men have a greater incidence of coronary artery disease (CAD) than women at the same age, that android fat distribution is associated with a greater incidence of CAD and that synthetic androgens exert an unfavourable effect upon plasma lipids.<sup><xref ref-type="bibr" rid="bibr5-1754045313487720">5</xref></sup> Thus, these findings seem to indicate that a hyper-androgenic state plays an adverse role on the CV system.</p>
<p>On the other hand, clinical studies have shown that testosterone has rather a protective effect on the CV function, as recently reviewed.<sup><xref ref-type="bibr" rid="bibr6-1754045313487720">6</xref></sup> Such a protection may be linked to its favourable effect on endothelial function and vasomotor tone, throughout metabolic and direct mechanisms of action on human vasculature.<sup><xref ref-type="bibr" rid="bibr5-1754045313487720">5</xref></sup> Observations supporting this hypothesis are that a hypo-androgenic state is associated with atherosclerosis and CAD in both aged men and women<sup><xref ref-type="bibr" rid="bibr7-1754045313487720">7</xref>,<xref ref-type="bibr" rid="bibr8-1754045313487720">8</xref></sup> and that testosterone replacement led to improvement of CV functions<sup><xref ref-type="bibr" rid="bibr9-1754045313487720">9</xref></sup> (see next paragraphs).</p>
<p>Taken together, all these data are not contradictory as both hyper- and hypo-testosterone conditions are therefore associated with CV dysfunction and CV risk, whereas testosterone levels within the physiological range seem to exert a protective CV effect.</p>
<p>Interestingly, the imbalance of testosterone and estrogen (i.e. T/E2 ratio) in male affected by CAD, rather than the absolute levels of androgens, has been recently found as a crucial parameter in modulating the effect of androgens on cardiac function in males.<sup><xref ref-type="bibr" rid="bibr10-1754045313487720">10</xref></sup></p>
<p>Ultimately, testosterone plays a multifaceted role on the CV system, with both direct and indirect influences,<sup><xref ref-type="bibr" rid="bibr9-1754045313487720">9</xref></sup> also depending upon the concurrent circulating levels of estrogens.</p>
</sec>
<sec id="sec3-1754045313487720"><title>Direct effects of testosterone on cardiovascular system according to gender</title>
<p>There is evidence that physiological testosterone levels improve endothelial function, peripheral vascular resistance and vasomotor tone, therefore acting directly on the vessel wall.<sup><xref ref-type="bibr" rid="bibr11-1754045313487720">11</xref></sup> This influence appears to be sex-dimorphic as differences in androgen receptor expression in human vasculature have been reported, with higher levels in men than women.<sup><xref ref-type="bibr" rid="bibr12-1754045313487720">12</xref></sup> Indeed, androgens show sex-specific endothelial responses, with testosterone inducing proliferation of male, but not female, rat lung endothelial cells.<sup><xref ref-type="bibr" rid="bibr13-1754045313487720">13</xref></sup></p>
<p>Studies on transsexual people have helped clarify the gender-specific effect of testosterone on CV function. Genetic females (female-to-male transsexuals) who underwent long-term administration of testosterone to maintain its plasma levels within the physiologic range found in men showed larger brachial artery diameter and reduced nitrate-induced response, but had similar endothelial function to that of age-matched female control subjects.<sup><xref ref-type="bibr" rid="bibr14-1754045313487720">14</xref></sup> Accordingly, an improvement in flow-mediated vasodilation was observed in estrogen-treated post-menopausal women who were also receiving parenteral testosterone.<sup><xref ref-type="bibr" rid="bibr15-1754045313487720">15</xref></sup> Thus, the sex-dimorphic effect of testosterone in women may be explained by the concurrent level of estrogenization.</p>
</sec>
<sec id="sec4-1754045313487720"><title>Indirect effects of testosterone on cardiovascular system according to gender</title>
<p>Testosterone has also an indirect effect on the CV system, i.e. by influencing vascular risk factors.</p>
<p>One of the main risk factors for CV disease is obesity, which is strongly associated with metabolic syndrome and is thought to have hormonal underpinnings. In men, obesity and metabolic syndrome are often associated with reductions in testosterone levels, which are, in turn, linked to increased inflammation.<sup><xref ref-type="bibr" rid="bibr9-1754045313487720">9</xref></sup> Indeed, serum testosterone concentrations have been found to be lower in obese than control male subjects<sup><xref ref-type="bibr" rid="bibr16-1754045313487720">16</xref>,<xref ref-type="bibr" rid="bibr17-1754045313487720">17</xref></sup> and physiological testosterone supplements may improve the lipid profile. Thus, inflammation may be reversed by androgen replacement in men. Testosterone-associated effects on weight gain and insulin resistance have been further confirmed by the 13-year longitudinal sub-study<sup><xref ref-type="bibr" rid="bibr18-1754045313487720">18</xref></sup> from the Multiple Risk Factor Intervention Trial (MRFIT) that was conducted on middle-aged men. The study found that the decrease in endogenous testosterone observed with age was associated with an increase in triglycerides and a decrease in high-density lipoprotein cholesterol, also showing a relation with increased low-density lipoprotein cholesterol. This study also indicated that the gradual decline in total testosterone levels observed in older men was related to lifestyle and psychosocial factors and with potentially unfavourable changes in triglycerides and high-density lipoprotein cholesterol.</p>
<p>On the other hand, in women, obesity and metabolic syndrome are associated with an increase in androgen levels, which are linked to inflammation; therefore, it is necessary to reduce androgens to lower inflammation.<sup><xref ref-type="bibr" rid="bibr19-1754045313487720">19</xref></sup> Accordingly, testosterone at supra-physiological doses may promote atherogenicity in women. In a study evaluating the effect of testosterone replacement on lipid profile in female-to-male transsexuals,<sup><xref ref-type="bibr" rid="bibr20-1754045313487720">20</xref></sup> a group of “androgenized” women, i.e. genetic females treated with testosterone esters after sex re-assignment, was compared to a control group of female transsexuals prior to starting androgen therapy and to a group of post-operative female transsexuals while on and after stopping the androgen therapy. Interestingly, the study showed that higher androgen levels due to long-term androgen therapy had adverse effects on lipid and lipoprotein profiles, suggesting that chronic exposure to increased levels of testosterone may promote atherogenicity in genetic females.</p>
<p>Consistently, another CV risk factor is atherosclerosis, which is one of the mechanisms underlying the association between low testosterone and CAD. It has been shown that endogenous testosterone has a protective role against the development and progression of atherosclerosis and its clinical complications.<sup><xref ref-type="bibr" rid="bibr21-1754045313487720">21</xref></sup> It has been consistently found that low androgen levels are associated with a more unhealthy artery wall in both sexes.<sup><xref ref-type="bibr" rid="bibr22-1754045313487720">22</xref></sup> However, gender differences in the development of atherosclerosis are evident in both humans and animal models of the disease. In several animal models of diet-induced atherosclerosis, males develop atherosclerotic plaques earlier and more broadly than females, independent of lipid levels.<sup><xref ref-type="bibr" rid="bibr23-1754045313487720">23</xref><xref ref-type="bibr" rid="bibr24-1754045313487720"/>–<xref ref-type="bibr" rid="bibr25-1754045313487720">25</xref></sup> Sex-specific differences in the development of atherosclerosis and CAD can not only simply be ascribed to a direct antiatherogenic effect of sex hormones but also to both direct effects within the vessel wall and to their influence on CV risk factors.<sup><xref ref-type="bibr" rid="bibr21-1754045313487720">21</xref></sup> Consistently, natural androgens inhibit atherosclerosis in male animal models of atherosclerosis.<sup><xref ref-type="bibr" rid="bibr25-1754045313487720">25</xref>,<xref ref-type="bibr" rid="bibr26-1754045313487720">26</xref></sup></p>
<p>Finally, low testosterone levels are associated with high blood pressure in middle-aged men.<sup><xref ref-type="bibr" rid="bibr9-1754045313487720">9</xref>,<xref ref-type="bibr" rid="bibr27-1754045313487720">27</xref></sup> However, acute and chronic testosterone administration do not significantly affect blood pressure<sup><xref ref-type="bibr" rid="bibr28-1754045313487720">28</xref></sup> and changes in blood pressure are indistinguishable from those induced by ageing.<sup><xref ref-type="bibr" rid="bibr29-1754045313487720">29</xref></sup> Thus, the biological underpinnings for why this occurs are still unknown. A possible mechanism may be related to a greater conversion of testosterone into estradiol in older men.<sup><xref ref-type="bibr" rid="bibr9-1754045313487720">9</xref></sup></p>
</sec>
<sec id="sec5-1754045313487720"><title>Androgens and CAD in women and men</title>
<p>Several studies have examined the relationship between testosterone and CAD in post-menopausal women<sup><xref ref-type="bibr" rid="bibr30-1754045313487720">30</xref><xref ref-type="bibr" rid="bibr31-1754045313487720"/>–<xref ref-type="bibr" rid="bibr32-1754045313487720">32</xref></sup> given the greater incidence of CAD after the menopause. The Rancho Bernardo Study,<sup><xref ref-type="bibr" rid="bibr30-1754045313487720">30</xref></sup> a population-based prospective study, has investigated testosterone levels of 651 post-menopausal women who did not take estrogen replacement therapy, showing that testosterone levels did not correlate with incidence of cardiac events. However, it is well known that women with hyper-androgenic conditions (e.g. polycystic ovary syndrome) may be associated with an unfavourable progression of atherosclerosis.<xref ref-type="bibr" rid="bibr5-1754045313487720">5</xref> It is therefore possible that the increased incidence of CAD observed in women after the menopause is linked to ovarian hormone deficiency and that androgen deprivation associated with ageing has the same effect in men. Although androgens may influence vasomotor tone, it is more likely that their effect upon the progression of atherosclerosis is related to the combination of their effect within the vessel wall and to their metabolic effects.<sup><xref ref-type="bibr" rid="bibr5-1754045313487720">5</xref></sup></p>
<p>Conversely, in women within the reproductive age, the role of endogenous androgens in the development of CAD is less clear. An ancillary study to the Coronary Artery Risk Development in Young Adults (CARDIA) study, a population-based multicenter cohort study with 20 years of follow-up, examined the prospective association of serum androgens and Sex Hormone Binding Globulin (SHBG) with subclinical coronary and carotid disease among young to middle-aged women. The study failed to find any associations for total or free testosterone with either coronary artery calcification or intima-media thickness, whereas SHBG levels were inversely associated with subclinical CV disease. On the contrary, the Dallas Heart Study,<sup><xref ref-type="bibr" rid="bibr33-1754045313487720">33</xref></sup> conducted in young women without known cardiac disease, showed that circulating free testosterone levels were independently and inversely associated with BNP and NT-proBNP, suggesting that testosterone, and not estradiol, mediates gender differences in natriuretic peptides. In addition, the study revealed an association between higher BMI and lean body mass with natriuretic peptides that could be mediated by testosterone.</p>
<p>Finally, several observations support the hypothesis that low levels of testosterone may contribute to CAD development in men. Male survivors of myocardial infarction have lower testosterone levels than controls<sup><xref ref-type="bibr" rid="bibr5-1754045313487720">5</xref>,<xref ref-type="bibr" rid="bibr34-1754045313487720">34</xref>,<xref ref-type="bibr" rid="bibr35-1754045313487720">35</xref></sup> and most cross-sectional studies have repetitively found an association between hypo-testosteronemia and CV morbidity<sup><xref ref-type="bibr" rid="bibr18-1754045313487720">18</xref>,<xref ref-type="bibr" rid="bibr36-1754045313487720">36</xref><xref ref-type="bibr" rid="bibr37-1754045313487720"/>–<xref ref-type="bibr" rid="bibr38-1754045313487720">38</xref></sup> and coronary events.<sup><xref ref-type="bibr" rid="bibr39-1754045313487720">39</xref>,<xref ref-type="bibr" rid="bibr40-1754045313487720">40</xref></sup> However, prospective studies showed the lack of a clear relationship between circulating testosterone and CAD,<sup><xref ref-type="bibr" rid="bibr41-1754045313487720">41</xref></sup> possibly due to the low event rate typical of such studies.<sup><xref ref-type="bibr" rid="bibr5-1754045313487720">5</xref></sup></p>
</sec>
<sec id="sec6-1754045313487720"><title>Testosterone supplementation in women and men</title>
<p>It is well known that female androgen insufficiency not only leads to the typical signs of reduced androgen exposure such as decreased muscle mass, reduced bone density, but also to an impairment in sexual drive, depressed mood and a decreased sense of well-being.<sup><xref ref-type="bibr" rid="bibr42-1754045313487720">42</xref></sup> Thus, androgen supplementation within physiological levels is of particular importance in metabolic, psychological and sexual functions in women.</p>
<p>A testosterone transdermal patch has been developed for the treatment of post-menopausal women with hypoactive sexual desire disorder, showing its utility.<sup><xref ref-type="bibr" rid="bibr15-1754045313487720">15</xref></sup> CV effects and safety of transdermal testosterone have been also assessed, showing that testosterone replacement is safe and associated with a favourable change of CV risk profile in post-menopausal women.<sup><xref ref-type="bibr" rid="bibr43-1754045313487720">43</xref></sup></p>
<p>In men and women with heart failure, testosterone supplementation has been shown to be effective. Indeed, lower testosterone levels are associated with heart failure severity, and when replaced, they may exert a beneficial metabolic effect on insulin resistance.<sup><xref ref-type="bibr" rid="bibr44-1754045313487720">44</xref></sup> In women with heart failure, testosterone deficiency is associated with reduced functional capacity and transdermal testosterone supplementation has been found to improve functional capacity, insulin resistance and muscle strength.<sup><xref ref-type="bibr" rid="bibr43-1754045313487720">43</xref></sup> Similarly, intramuscular injections of testosterone added to optimal medical therapy in elderly men with chronic heart failure have been found to improve exercise capacity, muscle strength and glucose metabolism.<sup><xref ref-type="bibr" rid="bibr45-1754045313487720">45</xref></sup></p>
<p>In men with CAD, testosterone administration favours peripheral blood flow, myocardial perfusion, and acute and chronic ischemia, and increases coronary vascular flow and vessel diameter at physiological concentrations.<sup><xref ref-type="bibr" rid="bibr14-1754045313487720">14</xref></sup></p>
<p>Thus, testosterone supplementation seems to be an effective and safe therapy for men and women with CV disease. On the other hand, in clinical trials where testosterone was used in patients with other preexisting CV conditions, its effects was either neutral or beneficial, as recently reviewed.<sup><xref ref-type="bibr" rid="bibr46-1754045313487720">46</xref></sup> In these trials, testosterone treatment efficacy was limited to an increase in hematocrit and a decrease in high-density lipoprotein cholesterol.</p>
</sec>
<sec id="sec7-1754045313487720" sec-type="conclusions"><title>Conclusions</title>
<p>Endogenous testosterone and its replacement within physiological levels display a favourable impact, throughout direct and indirect mechanisms, on CV function, both in men and women. Post-menopausal women and aged men seem to particularly benefit from testosterone supplementation therapy. However, future studies are strongly needed in order to deepen our understanding on this topic. In particular, upcoming research should investigate both differing doses and routes of administration of testosterone, e.g. the optimal degree-physiologic or supraphysiologic of androgen replacement, including much larger patient populations of both sexes, also exploring other clinical correlates.<sup><xref ref-type="bibr" rid="bibr47-1754045313487720">47</xref></sup> Prospective data from large, well-designed, long-term trials are particularly required to verify the CV efficacy/safety of testosterone treatment in both sexes.</p>
</sec>
</body>
<back>
<ref-list>
<title>References</title>
<ref id="bibr1-1754045313487720"><label>1</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Spoletini</surname><given-names>I</given-names></name><name><surname>Vitale</surname><given-names>C</given-names></name><name><surname>Malorni</surname><given-names>W</given-names></name><etal/></person-group>. <article-title>Sex differences in drug effects: interaction with sex hormones in adult life</article-title>. <source>Handb Exp Pharmacol</source> <year>2012</year>; <volume>214</volume>: <fpage>91</fpage>–<lpage>105</lpage>.</citation></ref>
<ref id="bibr2-1754045313487720"><label>2</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Franconi</surname><given-names>F</given-names></name><name><surname>Carru</surname><given-names>C</given-names></name><name><surname>Spoletini</surname><given-names>I</given-names></name><etal/></person-group>. <article-title>A GENS-based approach to cardiovascular pharmacology: impact on metabolism, pharmacokinetics and pharmacodynamics</article-title>. <source>Ther Deliv</source> <year>2012</year>; <volume>2</volume>: <fpage>1437</fpage>–<lpage>1453</lpage>.</citation></ref>
<ref id="bibr3-1754045313487720"><label>3</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mendelsohn</surname><given-names>ME</given-names></name><name><surname>Karas</surname><given-names>RH</given-names></name></person-group>. <article-title>Molecular and cellular basis of cardiovascular gender differences</article-title>. <source>Science</source> <year>2005</year>; <volume>308</volume>: <fpage>1583</fpage>–<lpage>1587</lpage>.</citation></ref>
<ref id="bibr4-1754045313487720"><label>4</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ruige</surname><given-names>JB</given-names></name><name><surname>Mahmoud</surname><given-names>AM</given-names></name><name><surname>De Bacquer</surname><given-names>D</given-names></name><etal/></person-group>. <article-title>Endogenous testosterone and cardiovascular disease in healthy men: a meta-analysis</article-title>. <source>Heart</source> <year>2012</year>; <volume>97</volume>: <fpage>870</fpage>–<lpage>875</lpage>.</citation></ref>
<ref id="bibr5-1754045313487720"><label>5</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rosano</surname><given-names>GM</given-names></name><name><surname>Cornoldi</surname><given-names>A</given-names></name><name><surname>Fini</surname><given-names>M</given-names></name></person-group>. <article-title>Effects of androgens on the cardiovascular system</article-title>. <source>J Endocrinol Invest</source> <year>2005</year>; <volume>28</volume>: <fpage>32</fpage>–<lpage>38</lpage>.</citation></ref>
<ref id="bibr6-1754045313487720"><label>6</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tirabassi</surname><given-names>G</given-names></name><name><surname>Gioia</surname><given-names>A</given-names></name><name><surname>Giovannini</surname><given-names>L</given-names></name><etal/></person-group>. <article-title>Testosterone and cardiovascular risk</article-title>. <source>Intern Emerg Med</source> <year>2013</year>; <volume>8</volume>(<issue>Suppl 1</issue>): <fpage>65</fpage>–<lpage>69</lpage>.</citation></ref>
<ref id="bibr7-1754045313487720"><label>7</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>English</surname><given-names>KM</given-names></name><name><surname>Mandour</surname><given-names>O</given-names></name><name><surname>Steeds</surname><given-names>RP</given-names></name><etal/></person-group>. <article-title>Men with coronary artery disease have lower levels of androgens than men with normal coronary angiograms</article-title>. <source>Eur Heart J</source> <year>2000</year>; <volume>21</volume>: <fpage>890</fpage>–<lpage>894</lpage>.</citation></ref>
<ref id="bibr8-1754045313487720"><label>8</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rosano</surname><given-names>GM</given-names></name><name><surname>Sheiban</surname><given-names>I</given-names></name><name><surname>Massaro</surname><given-names>R</given-names></name><etal/></person-group>. <article-title>Low testosterone levels are associated with coronary artery disease in male patients with angina</article-title>. <source>Int J Impot Res</source> <year>2007</year>; <volume>19</volume>: <fpage>176</fpage>–<lpage>182</lpage>.</citation></ref>
<ref id="bibr9-1754045313487720"><label>9</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Vitale</surname><given-names>C</given-names></name><name><surname>Mendelsohn</surname><given-names>ME</given-names></name><name><surname>Rosano</surname><given-names>GM</given-names></name></person-group>. <article-title>Gender differences in the cardiovascular effect of sex hormones</article-title>. <source>Nat Rev Cardiol</source> <year>2009</year>; <volume>6</volume>: <fpage>532</fpage>–<lpage>542</lpage>.</citation></ref>
<ref id="bibr10-1754045313487720"><label>10</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zheng</surname><given-names>HY</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Dai</surname><given-names>W</given-names></name><etal/></person-group>. <article-title>Imbalance of testosterone/estradiol promotes male CHD development</article-title>. <source>Biomed Mater Eng</source> <year>2012</year>; <volume>22</volume>: <fpage>179</fpage>–<lpage>185</lpage>.</citation></ref>
<ref id="bibr11-1754045313487720"><label>11</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jones</surname><given-names>RD</given-names></name><name><surname>Hugh Jones</surname><given-names>T</given-names></name><name><surname>Channer</surname><given-names>KS</given-names></name></person-group>. <article-title>The influence of testosterone upon vascular reactivity</article-title>. <source>Eur J Endocrinol</source> <year>2004</year>; <volume>151</volume>: <fpage>29</fpage>–<lpage>37</lpage>.</citation></ref>
<ref id="bibr12-1754045313487720"><label>12</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>McCrohon</surname><given-names>JA</given-names></name><name><surname>Death</surname><given-names>AK</given-names></name><name><surname>Nakhla</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Androgen receptor expression is greater in macrophages from male than from female donors. A sex difference with implications for atherogenesis</article-title>. <source>Circulation</source> <year>2000</year>; <volume>101</volume>: <fpage>224</fpage>–<lpage>226</lpage>.</citation></ref>
<ref id="bibr13-1754045313487720"><label>13</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Villablanca</surname><given-names>AC</given-names></name><name><surname>Jayachandran</surname><given-names>M</given-names></name><name><surname>Banka</surname><given-names>C</given-names></name></person-group>. <article-title>Atherosclerosis and sex hormones: current concepts</article-title>. <source>Clin Sci (Lond)</source> <year>2012</year>; <volume>119</volume>: <fpage>493</fpage>–<lpage>513</lpage>.</citation></ref>
<ref id="bibr14-1754045313487720"><label>14</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>McCredie</surname><given-names>RJ</given-names></name><name><surname>McCrohon</surname><given-names>JA</given-names></name><name><surname>Turner</surname><given-names>L</given-names></name><etal/></person-group>. <article-title>Vascular reactivity is impaired in genetic females taking high-dose androgens</article-title>. <source>J Am Coll Cardiol</source> <year>1998</year>; <volume>32</volume>: <fpage>1331</fpage>–<lpage>1335</lpage>.</citation></ref>
<ref id="bibr15-1754045313487720"><label>15</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Worboys</surname><given-names>S</given-names></name><name><surname>Kotsopoulos</surname><given-names>D</given-names></name><name><surname>Teede</surname><given-names>H</given-names></name><etal/></person-group>. <article-title>Evidence that parenteral testosterone therapy may improve endothelium-dependent and -independent vasodilation in postmenopausal women already receiving estrogen</article-title>. <source>J Clin Endocrinol Metab</source> <year>2001</year>; <volume>86</volume>: <fpage>158</fpage>–<lpage>161</lpage>.</citation></ref>
<ref id="bibr16-1754045313487720"><label>16</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pasquali</surname><given-names>R</given-names></name><name><surname>Vicennati</surname><given-names>V</given-names></name><name><surname>Gambineri</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Hormones and pathophysiology of obesity</article-title>. <source>Eat Weight Disord</source> <year>2001</year>; <volume>6</volume>: <fpage>9</fpage>–<lpage>20</lpage>.</citation></ref>
<ref id="bibr17-1754045313487720"><label>17</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mammi</surname><given-names>C</given-names></name><name><surname>Calanchini</surname><given-names>M</given-names></name><name><surname>Antelmi</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Androgens and adipose tissue in males: a complex and reciprocal interplay</article-title>. <source>Int J Endocrinol</source> <year>2012</year>; <volume>2012</volume>: <fpage>789653</fpage>–<lpage>789653</lpage>.</citation></ref>
<ref id="bibr18-1754045313487720"><label>18</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zmuda</surname><given-names>JM</given-names></name><name><surname>Cauley</surname><given-names>JA</given-names></name><name><surname>Kriska</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Longitudinal relation between endogenous testosterone and cardiovascular disease risk factors in middle-aged men. A 13-year follow-up of former Multiple Risk Factor Intervention Trial participants</article-title>. <source>Am J Epidemiol</source> <year>1997</year>; <volume>146</volume>: <fpage>609</fpage>–<lpage>617</lpage>.</citation></ref>
<ref id="bibr19-1754045313487720"><label>19</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Montalcini</surname><given-names>T</given-names></name><name><surname>Migliaccio</surname><given-names>V</given-names></name><name><surname>Ferro</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>Androgens for postmenopausal women's health?</article-title> <source>Endocrine</source> <year>2012</year>; <volume>42</volume>: <fpage>514</fpage>–<lpage>520</lpage>.</citation></ref>
<ref id="bibr20-1754045313487720"><label>20</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Goh</surname><given-names>HH</given-names></name><name><surname>Loke</surname><given-names>DF</given-names></name><name><surname>Ratnam</surname><given-names>SS</given-names></name></person-group>. <article-title>The impact of long-term testosterone replacement therapy on lipid and lipoprotein profiles in women</article-title>. <source>Maturitas</source> <year>1995</year>; <volume>21</volume>: <fpage>65</fpage>–<lpage>70</lpage>.</citation></ref>
<ref id="bibr21-1754045313487720"><label>21</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Corona</surname><given-names>G</given-names></name><name><surname>Rastrelli</surname><given-names>G</given-names></name><name><surname>Vignozzi</surname><given-names>L</given-names></name><etal/></person-group>. <article-title>Testosterone, cardiovascular disease and the metabolic syndrome</article-title>. <source>Best Pract Res Clin Endocrinol Metab</source> <year>2012</year>; <volume>25</volume>: <fpage>337</fpage>–<lpage>353</lpage>.</citation></ref>
<ref id="bibr22-1754045313487720"><label>22</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Naessen</surname><given-names>T</given-names></name><name><surname>Bergquist</surname><given-names>J</given-names></name><name><surname>Lind</surname><given-names>L</given-names></name><etal/></person-group>. <article-title>Higher endogenous estrogen levels in 70-year-old women and men: an endogenous response to counteract developing atherosclerosis?</article-title> <source>Menopause</source> <year>2012</year>; <volume>19</volume>: <fpage>1322</fpage>–<lpage>1328</lpage>.</citation></ref>
<ref id="bibr23-1754045313487720"><label>23</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bruck</surname><given-names>B</given-names></name><name><surname>Brehme</surname><given-names>U</given-names></name><name><surname>Gugel</surname><given-names>N</given-names></name><etal/></person-group>. <article-title>Gender-specific differences in the effects of testosterone and estrogen on the development of atherosclerosis in rabbits</article-title>. <source>Arterioscler Thromb Vasc Biol</source> <year>1997</year>; <volume>17</volume>: <fpage>2192</fpage>–<lpage>2199</lpage>.</citation></ref>
<ref id="bibr24-1754045313487720"><label>24</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>von Dehn</surname><given-names>G</given-names></name><name><surname>von Dehn</surname><given-names>O</given-names></name><name><surname>Volker</surname><given-names>W</given-names></name><etal/></person-group>. <article-title>Atherosclerosis in apolipoprotein E-deficient mice is decreased by the suppression of endogenous sex hormones</article-title>. <source>Horm Metab Res</source> <year>2001</year>; <volume>33</volume>: <fpage>110</fpage>–<lpage>114</lpage>.</citation></ref>
<ref id="bibr25-1754045313487720"><label>25</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Alexandersen</surname><given-names>P</given-names></name><name><surname>Haarbo</surname><given-names>J</given-names></name><name><surname>Byrjalsen</surname><given-names>I</given-names></name><etal/></person-group>. <article-title>Natural androgens inhibit male atherosclerosis: a study in castrated, cholesterol-fed rabbits</article-title>. <source>Circ Res</source> <year>1999</year>; <volume>84</volume>: <fpage>813</fpage>–<lpage>819</lpage>.</citation></ref>
<ref id="bibr26-1754045313487720"><label>26</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Adams</surname><given-names>MR</given-names></name><name><surname>Williams</surname><given-names>JK</given-names></name><name><surname>Kaplan</surname><given-names>JR</given-names></name></person-group>. <article-title>Effects of androgens on coronary artery atherosclerosis and atherosclerosis-related impairment of vascular responsiveness</article-title>. <source>Arterioscler Thromb Vasc Biol</source> <year>1995</year>; <volume>15</volume>: <fpage>562</fpage>–<lpage>570</lpage>.</citation></ref>
<ref id="bibr27-1754045313487720"><label>27</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Khaw</surname><given-names>KT</given-names></name></person-group>. <article-title>Comparison of the early outcome of acute myocardial infarction in women and men</article-title>. <source>N Engl J Med</source> <year>1998</year>; <volume>338</volume>: <fpage>1543; author reply 4</fpage>–<lpage>1543; author reply 4</lpage>.</citation></ref>
<ref id="bibr28-1754045313487720"><label>28</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kapoor</surname><given-names>D</given-names></name><name><surname>Goodwin</surname><given-names>E</given-names></name><name><surname>Channer</surname><given-names>KS</given-names></name><etal/></person-group>. <article-title>Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes</article-title>. <source>Eur J Endocrinol</source> <year>2006</year>; <volume>154</volume>: <fpage>899</fpage>–<lpage>906</lpage>.</citation></ref>
<ref id="bibr29-1754045313487720"><label>29</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Muller</surname><given-names>M</given-names></name><name><surname>van der Schouw</surname><given-names>YT</given-names></name><name><surname>Thijssen</surname><given-names>JH</given-names></name><etal/></person-group>. <article-title>Endogenous sex hormones and cardiovascular disease in men</article-title>. <source>J Clin Endocrinol Metab</source> <year>2003</year>; <volume>88</volume>: <fpage>5076</fpage>–<lpage>5086</lpage>.</citation></ref>
<ref id="bibr30-1754045313487720"><label>30</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Barrett-Connor</surname><given-names>E</given-names></name><name><surname>Goodman-Gruen</surname><given-names>D</given-names></name></person-group>. <article-title>Prospective study of endogenous sex hormones and fatal cardiovascular disease in postmenopausal women</article-title>. <source>Bmj</source> <year>1995</year>; <volume>311</volume>: <fpage>1193</fpage>–<lpage>1196</lpage>.</citation></ref>
<ref id="bibr31-1754045313487720"><label>31</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Phillips</surname><given-names>GB</given-names></name><name><surname>Pinkernell</surname><given-names>BH</given-names></name><name><surname>Jing</surname><given-names>TY</given-names></name></person-group>. <article-title>Relationship between serum sex hormones and coronary artery disease in postmenopausal women</article-title>. <source>Arterioscler Thromb Vasc Biol</source> <year>1997</year>; <volume>17</volume>: <fpage>695</fpage>–<lpage>701</lpage>.</citation></ref>
<ref id="bibr32-1754045313487720"><label>32</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bernini</surname><given-names>GP</given-names></name><name><surname>Sgro</surname><given-names>M</given-names></name><name><surname>Moretti</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Endogenous androgens and carotid intimal-medial thickness in women</article-title>. <source>J Clin Endocrinol Metab</source> <year>1999</year>; <volume>84</volume>: <fpage>2008</fpage>–<lpage>2012</lpage>.</citation></ref>
<ref id="bibr33-1754045313487720"><label>33</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname><given-names>AY</given-names></name><name><surname>Abdullah</surname><given-names>SM</given-names></name><name><surname>Jain</surname><given-names>T</given-names></name><etal/></person-group>. <article-title>Associations among androgens, estrogens, and natriuretic peptides in young women: observations from the Dallas Heart Study</article-title>. <source>J Am Coll Cardiol</source> <year>2007</year>; <volume>49</volume>: <fpage>109</fpage>–<lpage>116</lpage>.</citation></ref>
<ref id="bibr34-1754045313487720"><label>34</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sewdarsen</surname><given-names>M</given-names></name><name><surname>Vythilingum</surname><given-names>S</given-names></name><name><surname>Jialal</surname><given-names>I</given-names></name><etal/></person-group>. <article-title>Abnormalities in sex hormones are a risk factor for premature manifestation of coronary artery disease in South African Indian men</article-title>. <source>Atherosclerosis</source> <year>1990</year>; <volume>83</volume>: <fpage>111</fpage>–<lpage>117</lpage>.</citation></ref>
<ref id="bibr35-1754045313487720"><label>35</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Phillips</surname><given-names>GB</given-names></name><name><surname>Pinkernell</surname><given-names>BH</given-names></name><name><surname>Jing</surname><given-names>TY</given-names></name></person-group>. <article-title>The association of hypotestosteronemia with coronary artery disease in men</article-title>. <source>Arterioscler Thromb</source> <year>1994</year>; <volume>14</volume>: <fpage>701</fpage>–<lpage>706</lpage>.</citation></ref>
<ref id="bibr36-1754045313487720"><label>36</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Barrett-Connor</surname><given-names>E</given-names></name><name><surname>Khaw</surname><given-names>KT</given-names></name></person-group>. <article-title>Endogenous sex hormones and cardiovascular disease in men. A prospective population-based study</article-title>. <source>Circulation</source> <year>1988</year>; <volume>78</volume>: <fpage>539</fpage>–<lpage>545</lpage>.</citation></ref>
<ref id="bibr37-1754045313487720"><label>37</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Barrett-Connor</surname><given-names>E</given-names></name><name><surname>Khaw</surname><given-names>KT</given-names></name><name><surname>Yen</surname><given-names>SS</given-names></name></person-group>. <article-title>A prospective study of dehydroepiandrosterone sulfate, mortality, and cardiovascular disease</article-title>. <source>N Engl J Med</source> <year>1986</year>; <volume>315</volume>: <fpage>1519</fpage>–<lpage>1524</lpage>.</citation></ref>
<ref id="bibr38-1754045313487720"><label>38</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hautanen</surname><given-names>A</given-names></name><name><surname>Manttari</surname><given-names>M</given-names></name><name><surname>Manninen</surname><given-names>V</given-names></name><etal/></person-group>. <article-title>Adrenal androgens and testosterone as coronary risk factors in the Helsinki Heart Study</article-title>. <source>Atherosclerosis</source> <year>1994</year>; <volume>105</volume>: <fpage>191</fpage>–<lpage>200</lpage>.</citation></ref>
<ref id="bibr39-1754045313487720"><label>39</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jeppesen</surname><given-names>LL</given-names></name><name><surname>Jorgensen</surname><given-names>HS</given-names></name><name><surname>Nakayama</surname><given-names>H</given-names></name><etal/></person-group>. <article-title>Decreased serum testosterone in men with acute ischemic stroke</article-title>. <source>Arterioscler Thromb Vasc Biol</source> <year>1996</year>; <volume>16</volume>: <fpage>749</fpage>–<lpage>754</lpage>.</citation></ref>
<ref id="bibr40-1754045313487720"><label>40</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>D'Amico</surname><given-names>AV</given-names></name><name><surname>Chen</surname><given-names>MH</given-names></name><name><surname>Renshaw</surname><given-names>AA</given-names></name><etal/></person-group>. <article-title>Causes of death in men undergoing androgen suppression therapy for newly diagnosed localized or recurrent prostate cancer</article-title>. <source>Cancer</source> <year>2008</year>; <volume>113</volume>: <fpage>3290</fpage>–<lpage>3297</lpage>.</citation></ref>
<ref id="bibr41-1754045313487720"><label>41</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rosano</surname><given-names>GM</given-names></name></person-group>. <article-title>Androgens and coronary artery disease.. A sex-specific effect of sex hormones?</article-title> <source>Eur Heart J</source> <year>2000</year>; <volume>21</volume>: <fpage>868</fpage>–<lpage>871</lpage>.</citation></ref>
<ref id="bibr42-1754045313487720"><label>42</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yasui</surname><given-names>T</given-names></name><name><surname>Matsui</surname><given-names>S</given-names></name><name><surname>Tani</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Androgen in postmenopausal women</article-title>. <source>J Med Invest</source> <year>2012</year>; <volume>59</volume>: <fpage>12</fpage>–<lpage>27</lpage>.</citation></ref>
<ref id="bibr43-1754045313487720"><label>43</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Iellamo</surname><given-names>F</given-names></name><name><surname>Volterrani</surname><given-names>M</given-names></name><name><surname>Caminiti</surname><given-names>G</given-names></name><etal/></person-group>. <article-title>Testosterone therapy in women with chronic heart failure: a pilot double-blind, randomized, placebo-controlled study</article-title>. <source>J Am Coll Cardiol</source> <year>2012</year>; <volume>56</volume>: <fpage>1310</fpage>–<lpage>1316</lpage>.</citation></ref>
<ref id="bibr44-1754045313487720"><label>44</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sacca</surname><given-names>L</given-names></name></person-group>. <article-title>Heart failure as a multiple hormonal deficiency syndrome</article-title>. <source>Circ Heart Fail</source> <year>2009</year>; <volume>2</volume>: <fpage>151</fpage>–<lpage>156</lpage>.</citation></ref>
<ref id="bibr45-1754045313487720"><label>45</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Caminiti</surname><given-names>G</given-names></name><name><surname>Volterrani</surname><given-names>M</given-names></name><name><surname>Iellamo</surname><given-names>F</given-names></name><etal/></person-group>. <article-title>Effect of long-acting testosterone treatment on functional exercise capacity, skeletal muscle performance, insulin resistance, and baroreflex sensitivity in elderly patients with chronic heart failure a double-blind, placebo-controlled, randomized study</article-title>. <source>J Am Coll Cardiol</source> <year>2009</year>; <volume>54</volume>: <fpage>919</fpage>–<lpage>927</lpage>.</citation></ref>
<ref id="bibr46-1754045313487720"><label>46</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Carson</surname><given-names>CC</given-names><suffix>3rd</suffix></name><name><surname>Rosano</surname><given-names>G</given-names></name></person-group>. <article-title>Exogenous testosterone, cardiovascular events, and cardiovascular risk factors in elderly men: a review of trial data</article-title>. <source>J Sex Med</source> <year>2012</year>; <volume>9</volume>: <fpage>54</fpage>–<lpage>67</lpage>.</citation></ref>
<ref id="bibr47-1754045313487720"><label>47</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Armstrong</surname><given-names>PW</given-names></name><name><surname>Ezekowitz</surname><given-names>JA</given-names></name></person-group>. <article-title>Testosterone therapy in women with heart failure “why can't a woman be more like a man?”</article-title>. <source>J Am Coll Cardiol</source> <year>2012</year>; <volume>56</volume>: <fpage>1317</fpage>–<lpage>1319</lpage>.</citation></ref>
</ref-list>
</back>
</article>